Urticaria (Hives)

Urticaria, commonly known as hives, is a skin reaction that causes red or skin-colored, itchy welts. They can range in size from small spots to large blotches several inches in diameter. Individual welts typically appear and fade repeatedly as the reaction runs its course.

• Acute Urticaria: Hives lasting less than six weeks. Commonly triggered by foods, medications, insect bites, or acute viral infections.
• Chronic Urticaria: Hives lasting longer than six weeks, appearing daily or almost daily. Chronic Spontaneous Urticaria (CSU) has no identifiable external trigger and is largely autoimmune in nature.
• Angioedema: Deep tissue swelling that often occurs alongside hives, typically affecting the lips, eyes, hands, or throat. Swelling of the throat requires immediate emergency intervention.

The first line of defense for both acute and chronic hives is blocking the histamine receptors responsible for the itching and vascular leakage.

Second-generation H1 Antihistamines

Non-drowsy daily antihistamines such as Cetirizine (Zyrtec), Levocetirizine (Xyzal), Loratadine (Claritin), and Fexofenadine (Allegra). For chronic hives, guidelines recommend escalating the dosage up to four times the standard daily dose under medical supervision before switching therapies.

H2 Blockers & H1 Combinations

Adding H2 blockers like Famotidine (Pepcid) is often useful as they block histamine receptors in the blood vessels, acting synergistically with standard H1 antihistamines to reduce welt size.

For patients with chronic hives who do not achieve clearance with high-dose antihistamines, targeted biologics are the standard of care.

Omalizumab (Xolair)

A recombinant DNA-derived monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It is administered as an injection once every four weeks and provides rapid, high-efficacy relief for the majority of chronic spontaneous urticaria patients.

Clinical trials are investigating newer biologics targeting IgE receptors and oral JAK inhibitors to clear hives without injections.

• # **NCT06921355:** A Phase III randomized trial to evaluate safety and efficacy of a next-generation IgE-targeting biologic in patients with antihistamine-resistant CSU.
• # **NCT07019245:** Evaluating the safety and efficacy of a selective daily oral JAK inhibitor for moderate-to-severe chronic inducible urticaria.
• # **NCT07118299:** A clinical study assessing a novel topical transient receptor potential channel blocker for localized hive outbreaks and swelling.

If you or a loved one has recently been diagnosed with Urticaria (Hives), take these active steps to manage symptoms and track triggers:

1. Establish a Daily Non-Drowsy Regimen: Work with an allergist or dermatologist to find the correct non-drowsy H1 antihistamine dose. Many chronic spontaneous urticaria patients require up to four times the standard daily dose to achieve control.
2. Track Outbreaks and Triggers: Keep a detailed log of when hives occur, their severity, and potential triggers (e.g., heat, cold, exercise, pressure from tight clothing, specific foods, or stress).
3. Avoid Physical Irritants: Wear loose, breathable cotton clothing to prevent friction welts. Avoid hot baths or showers, which dilate blood vessels and release more histamine.
4. Understand Angioedema Warnings: Know the signs of deep-tissue swelling. If you experience swelling of the lips, tongue, or throat, or have difficulty swallowing or breathing, seek emergency medical care immediately.

Q: Can stress cause hives?
A: Yes. While stress does not typically cause acute allergic hives, it is a well-established trigger that can severely exacerbate outbreaks of Chronic Spontaneous Urticaria.

Q: What is the difference between hives and a rash?
A: Hives are characterized by transient welts (wheals) that move around the body, with individual welts disappearing within 24 hours while new ones appear elsewhere. Standard eczema or Contact Dermatitis rashes are persistent and do not move.